Literature DB >> 12612277

Frequency of surgery among children who have adenotonsillar hypertrophy and improve after treatment with nasal beclomethasone.

Gaetano Criscuoli1, Stefania D'Amora, Giuseppe Ripa, Giovanni Cinquegrana, Nicola Mansi, Nicola Impagliazzo, Alfredo Pisacane.   

Abstract

OBJECTIVE: To describe the long-term outcome of a cohort of children with symptomatic adenotonsillar hypertrophy treated with aqueous nasal beclomethasone.
METHODS: The children enrolled completed a 4-week single-blind, saline solution controlled crossover study of aqueous beclomethasone (total: 400 micro g/d). In a 24-week open-label follow-on study, beclomethasone 200 micro g/d was offered to all patients. During a 100-week follow-up, the degree of nasal obstruction and the frequency of adenotonsillectomy were assessed.
RESULTS: Fifty-three children of the 60 enrolled completed the study. After the 4-week crossover trial, the severity of nasal obstruction of 24 children (45%) significantly decreased during the use of nasal steroids, but no child improved when saline solution was used. At 24, 52, and 100 weeks, the 24 children who had initially improved showed a significant decrease of the severity of nasal obstruction and of the frequency of adenotonsillectomy (54% vs 83%) compared with the 29 children who had not responded after the initial steroidal therapy.
CONCLUSIONS: Evidence from this study suggests that 45% of children with adenoidal hypertrophy improved after 2 weeks of steroidal therapy. Among these children, an additional 24-week treatment at a lower steroid dosage was associated with a significant 52- and 100-week clinical improvement and with reduction of adenotonsillectomy compared with children (55%) who had not responded after the initial 2-week steroidal therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12612277     DOI: 10.1542/peds.111.3.e236

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  13 in total

1.  Does adenoid hypertrophy affect disease severity in children with allergic rhinitis?

Authors:  Mahmut Dogru; Muhammed Fatih Evcimik; Omer Faruk Calim
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-07-12       Impact factor: 2.503

Review 2.  Antileukotrienes in adenotonsillar hypertrophy: a review of the literature.

Authors:  Murat Kar; Niyazi Altıntoprak; Nuray Bayar Muluk; Seckin Ulusoy; Sameer Ali Bafaqeeh; Cemal Cingi
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-03-16       Impact factor: 2.503

3.  The role of mometasone furoate nasal spray in the treatment of adenoidal hypertrophy in the adolescents: a prospective, randomized, cross-over study.

Authors:  Huseyin Baki Yilmaz; Saban Celebi; Asli Sahin-Yilmaz; Cagatay Oysu
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-05       Impact factor: 2.503

4.  [Medicinal treatment of breathing disorders in adenotonsillar hyperplasia].

Authors:  M S Urschitz; C F Poets; B A Stuck; A Wiater; F Kirchhoff
Journal:  HNO       Date:  2014-08       Impact factor: 1.284

5.  Anti-inflammatory medications for obstructive sleep apnoea in children.

Authors:  Stefan Kuhle; Dorle U Hoffmann; Souvik Mitra; Michael S Urschitz
Journal:  Cochrane Database Syst Rev       Date:  2020-01-17

6.  Adenoid Vegetation in Children with Allergic Rhinitis.

Authors:  Gülpembe Bozkurt; Senem Kurt Dizdar; Arzu Yasemin Korkut; Berna Uslu Coşkun
Journal:  Turk Arch Otorhinolaryngol       Date:  2015-12-01

Review 7.  Intranasal corticosteroids for nasal airway obstruction in children with moderate to severe adenoidal hypertrophy.

Authors:  Linjie Zhang; Raúl A Mendoza-Sassi; Juraci A César; Neil K Chadha
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

8.  Turkish Guideline for Diagnosis and Treatment of Allergic Rhinitis (ART).

Authors:  Mustafa Cenk Ecevit; Müge Özcan; İlknur Haberal Can; Emel Çadallı Tatar; Serdar Özer; Erkan Esen; Doğan Atan; Sercan Göde; Çağdaş Elsürer; Aylin Eryılmaz; Berna Uslu Coşkun; Zahide Mine Yazıcı; Mehmet Emre Dinç; Fatih Özdoğan; Kıvanç Günhan; Nagihan Bilal; Arzu Yasemin Korkut; Fikret Kasapoğlu; Bilge Türk; Ela Araz Server; Özlem Önerci Çelebi; Tuğçe Şimşek; Rauf Oğuzhan Kum; Mustafa Kemal Adalı; Erdem Eren; Nesibe Gül Yüksel Aslıer; Tuba Bayındır; Aslı Çakır Çetin; Ayşe Enise Göker; Işıl Adadan Güvenç; Sabri Köseoğlu; Gül Soylu Özler; Ethem Şahin; Aslı Şahin Yılmaz; Ceren Güne; Gökçe Aksoy Yıldırım; Bülent Öca; Mehmet Durmuşoğlu; Yunus Kantekin; Süay Özmen; Gözde Orhan Kubat; Serap Köybaşı Şanal; Emine Elif Altuntaş; Adin Selçuk; Haşmet Yazıcı; Deniz Baklacı; Atılay Yaylacı; Deniz Hancı; Sedat Doğan; Vural Fidan; Kemal Uygur; Nesil Keleş; Cemal Cingi; Bülent Topuz; Salih Çanakçıoğlu; Metin Önerci
Journal:  Turk Arch Otorhinolaryngol       Date:  2021-05

9.  Safety and Efficacy of Maxitrol in Pediatric Age Group Below Two Years With Adenoid Hypertrophy: A Retrospective Cohort Study.

Authors:  Mohammed Halawani; Abdullah Alkhaldi; Abdullah Almajed; Ahmed Almutairi; Maali Alrashed; Nouf Albakeet; Wala Alshiha; Omar Aldibasi; Jaber Alshammari
Journal:  Cureus       Date:  2021-04-28

10.  Role of intranasal steroid in the prevention of recurrent nasal symptoms after adenoidectomy.

Authors:  Tamer S Sobhy
Journal:  Int J Otolaryngol       Date:  2013-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.